Maurizio Rocchetti

发表

A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation

Piet H. Van Der Graaf, Massimiliano Germani, Francesca Del Bene, 2013, Comput. Methods Programs Biomed..

A Bayesian Nonparametric Approach to AUC Determination in Population Studies

Giuseppe De Nicolao, Riccardo Bellazzi, Paolo Magni, 2000 .

Assessing drug effect from distributional data: A population approach with application to Duchenne Muscular Dystrophy treatment

Giuseppe De Nicolao, Maurizio Rocchetti, S. M. Lavezzi, 2019, Comput. Methods Programs Biomed..

A Versatile Simulator for Validation of Hormone Pulse Detection Algorithms

G. De Nicolao, V. Guardabasso, Maurizio Rocchetti, 1988 .

A Minimal Model of Tumor Growth Inhibition

Giuseppe De Nicolao, Paolo Magni, Monica Simeoni, 2008, IEEE Transactions on Biomedical Engineering.

Modeling of human tumor xenografts and dose rationale in oncology.

Paolo Magni, Giuseppe De Nicolao, Monica Simeoni, 2013, Drug discovery today. Technologies.

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

Paola Storici, Maurizio Rocchetti, Enrico Pesenti, 2006, Journal of medicinal chemistry.

In vitro cell growth pharmacodynamic studies: a new nonparametric approach to determining the relative importance of drug concentration and treatment time

Giuseppe De Nicolao, Paolo Magni, Italo Poggesi, 2003, Cancer Chemotherapy and Pharmacology.

Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

Paolo Magni, Giuseppe De Nicolao, Monica Simeoni, 2004, Cancer Research.

Re: Antitumor efficacy testing in rodents.

Italo Poggesi, Massimiliano Germani, Maurizio Rocchetti, 2009, Journal of the National Cancer Institute.

Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study.

Patrizia Crivori, Alan G. E. Wilson, Alan G E Wilson, 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors

Maurizio Rocchetti, J. Verweij, J. Nortier, 2008 .

Predictive pharmacokinetic–pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts

Giuseppe De Nicolao, Paolo Magni, Italo Poggesi, 2013, Cancer Chemotherapy and Pharmacology.

Histological effects of givinostat in boys with Duchenne muscular dystrophy

Giuseppe De Nicolao, Marika Pane, Maurizio Rocchetti, 2016, Neuromuscular Disorders.

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer

Paola Storici, Cristina Alli, Maurizio Rocchetti, 2007, Molecular Cancer Therapeutics.